Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and duration of block with TTX but not bupivacaine. An in vitro toxicity assay showed a wide range...

A medical device comprising: an array of microneedles and a coating disposed on the microneedles wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine prilocaine and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine ropivacaine bupivacaine procaine and a combination thereof; wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in t...

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide preferably ziconotide in combination with an analgesic selected from the group consisting of morphine bupivacaine clonidine hydromorphone baclofen fentanyl buprenorphine and sufentanil or its pharmaceutically acceptable salts thereof wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the ...

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed.

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed.

Disclosed are bupivacaine transdermal delivery systems, and related methods.

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide preferably ziconotide in combination with an analgesic selected from the group consisting of morphine bupivacaine clonidine hydromorphone baclofen fentanyl buprenorphine and sufentanil or its pharmaceutically acceptable salts thereof wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the ...